Anokion announces FDA clearance of IND application for ANK-700 to treat multiple sclerosis

This article was originally published here

Anokion plans to initiate a multi-center, Phase 1 clinical trial of ANK-700 in people with MS by the end of this year. “Multiple sclerosis remains a devastating disease

The post Anokion announces FDA clearance of IND application for ANK-700 to treat multiple sclerosis appeared first on Pharmaceutical Business review.